ASX Announcements


 
    Trading Halt  
 
    Island investor presentation  
 
    Dosing complete in ISLA-101 SAD study  
 
    Quarterly Activity Report and Appendix 4C  
 
    Third cohort dosed in ISLA-101 Single Ascending Dose study  
 
    Notification of cessation of securities - ILA  
 
    Approval to commence dosing 3rd cohort of ISLA-101 SAD study  
 
    R&D Tax Incentive loan facility secured with Radium Capital  
 
    Second cohort dosed in ISLA-101 Single Ascending Dose study  
 
    Company Secretary Appointment/Resignation  
 
    Island doses first cohort in ISLA-101 clinical trial  
 
    Replacement Constitution  
 
    Replacement - Results of AGM  
 
    Results of AGM  
 
    Annual General Meeting MD Presentation  
 
    Screening commences for ISLA-101 Single Ascending Dose Study  
 
    Island receives R&D tax refund for FY2023  
 
    Island receives ethics approval for ISLA-101 study  
 
    ILA releases updated investor presentation  
 
    ILA granted key Australian patent for ISLA-101  
 
    Island Annual General Meeting online link for shareholders  
 
    Quarterly Activity Report & Appendix 4C  
 
    Annual Report to Shareholders  
 
    Letter to Shareholders, Notice of AGM & Proxy Form  
 
    Date of AGM & Closing Date for Director Nominations  
 
    ISLA-101 Single Ascending Dose study update  
 
    Island Pharmaceuticals granted key U.S. patent for ISLA-101  
 
    Appendix 4G  
 
    Corporate Governance Statement  
 
    Appendix 4E & Annual Report  
 
    Quarterly Activity Report & Appendix 4C  
 
    US grant funding to support ISLA-101 clinical development  
 
    Island receives FDA go-ahead for ISLA-101 program  
 
    Replacement - Change in substantial holding  
 
    Change in substantial holding  
 
    Quarterly Activity Report & Appendix 4C  
 
    Island submits responses to FDA questions for ISLA-101  
 
    Application for quotation of securities - ILA  
 
    Appendix 3Y - Albert Hansen  
 
    Notification of cessation of securities - ILA  
 
    Release of Securities from Escrow  
 
    Appendix 4D & Half-Year Financial Statements  
 
    Change in substantial holding  
 
    ILA receives additional FDA feedback on IND for ISLA 101  
 
    Quarterly Activity Report & Appendix 4C  
 
    Island receives FDA feedback on Phase 2a clinical study  
 
    ILA submits IND to US FDA for Phase 2a PEACH clinical trial  
 
    Notice of Change of Auditor  
 
    Island online investor briefing presentation  
 
    IRB approval received for ISLA101 Phase 2a clinical trial  
 
    ISLA101 drug product achieves stability milestone  
 
    Island investor briefing invitation  
 
    ISLA-101 trial update and investor presentation  
 
    Island to present at World Antiviral Congress 2022  
 
    Change in substantial holding  
 
    Results of AGM  
 
    Annual General Meeting MD Presentation  
 
    ILA granted key Canadian patent for ISLA-101  
 
    Positive analytical results for ISLA-101 capsules  
 
    Island ShareCafe webinar presentation  
 
    Quarterly Activity Report & Appendix 4C  
 
    ISLA-101 manufacturing progress  
 
    Annual Report to Shareholders  
 
    Letter to Shareholders, Notice of AGM & Proxy Form  
 
    Date of AGM & Closing Date for Director Nominations  
 
    Appendix 4G  
 
    Corporate Governance Statement  
 
    Appendix 4E & Annual Report  
 
    Appendix 3Y - David Foster  
 
    Quarterly Activity Report & Appendix 4C  
 
    Notification regarding unquoted securities - ILA  
 
    Dr Amy Patick joins Island Scientific Advisory Board  
 
    Appendix 3Y - David Foster  
 
    Island to present at BIO International Convention  
 
    ISLA-101 manufacturing and timeline update  
 
    Change in substantial holding  
 
    Quarterly Activity Report & Appendix 4C  
 
    Updated Investor Presentation & Conference Participation  
 
    Change in substantial holding  
 
    Release of Securities from Escrow  
 
    Appendix 4D & Half-Year Financial Statements  
 
    Application for quotation of securities - ILA  
 
    Updated Investor Presentation & Webinar Invitation  
 
    Change in substantial holding  
 
    Release of Securities from Escrow  
 
    Quarterly Activity Report & Appendix 4C  
 
    Island executes PEACH clinical study CRO agreement  
 
    Change in substantial holding  
 
    Appendix 3Y - Anna Lavelle  
 
    Appendix 3Y - Albert Hansen  
 
    Appendix 3Y - David Brookes  
 
    Cleansing Notice  
 
    Application for quotation of securities - ILA  
 
    Results of Annual General Meeting  
 
    Annual General Meeting MD Presentation  
 
    Annual General Meeting Chair Address  
 
    ISLA-101 Phase 2a clinical trial update  
 
    Quarterly Activity Report & Appendix 4C  
 
    Change in substantial holding  
 
    Proposed issue of securities - ILA  
 
    Annual Report to shareholders  
 
    Letter to Shareholders & Notice of Annual General Meeting  
 
    Change in substantial holding  
 
    Updated Investor Presentation  
 
    Release of Securities from Voluntary Escrow  
 
    Date of AGM & Closing Date for Director Nominations  
 
    Island updates API agreement  
 
    Appendix 4G  
 
    Corporate Governance Statement  
 
    Appendix 4E & Annual Report  
 
    Griffith Uni Anti-Viral Molecule Screening Collaboration  
 
    Change in substantial holding  
 
    Island granted key Australian patent for ISLA-101  
 
    Becoming a substantial holder  
 
    Quarterly Activity Report & Appendix 4C  
 
    Island secures API - shortens timeline to clinical trials  
 
    ASEAN Dengue Day - Investor briefing notification  
 
    Island Pharmaceuticals granted key United States patent  
 
    Island lists on the ASX following oversubscribed IPO  
 
    Island Pharmaceuticals IPO Investor Presentation  
 
    Appendix 3X - Anna Lavelle  
 
    Appendix 3X - David Brookes  
 
    Appendix 3X - Paul MacLeman  
 
    Appendix 3X - David Foster  
 
    Appendix 3X - Albert Hansen  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Pre-Quotation Disclosure Statement  
 
    Top 20 Holders  
 
    Distribution Schedule  
 
    Securities Trading Policy  
 
    U.S. Option Terms  
 
    Option Terms  
 
    Employee Option Terms  
 
    Employee Incentive Plan Rules  
 
    Financial Report 30 June 2020  
 
    Financial Report half year ended 31 December 2020  
 
    Isla Pharmaceuticals, Inc. Financial Report 31 Dec 20 & 19  
 
    Isla Pharmaceuticals, Inc. Financial Report 31 December 2018  
 
    Constitution  
 
    Prospectus  
 
    Appendix 1A and Information Form and Checklist  
 
    Admission and Commencement of Official Quotation